Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Use of the PRO Onc Assay to Assess HER2 Overexpression and Activation in Patients With Metastatic Breast Cancer Whose Tumors Are HER2-Negative by Standard FISH Testing

NCT01048099 is registered in ClinicalTrials.gov with SCRI Development Innovations, LLC as lead sponsor.

NCT NCT01048099
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01048099 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Use of the PRO Onc Assay to Assess HER2 Overexpression and Activation in Patients With Metastatic Breast Cancer Whose Tumors Are HER2-Negative by Standard FISH Testing
Lead sponsor
SCRI Development Innovations, LLC
Phase
Not applicable
Overall status
Completed
Start date
January 31, 2011
Completion date
July 31, 2014
Enrollment
283 (actual)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer